JP2001517245A5 - - Google Patents

Download PDF

Info

Publication number
JP2001517245A5
JP2001517245A5 JP1999500938A JP50093899A JP2001517245A5 JP 2001517245 A5 JP2001517245 A5 JP 2001517245A5 JP 1999500938 A JP1999500938 A JP 1999500938A JP 50093899 A JP50093899 A JP 50093899A JP 2001517245 A5 JP2001517245 A5 JP 2001517245A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP1999500938A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001517245A (ja
Filing date
Publication date
Priority claimed from GBGB9714316.8A external-priority patent/GB9714316D0/en
Priority claimed from GBGB9800680.2A external-priority patent/GB9800680D0/en
Application filed filed Critical
Priority claimed from PCT/US1998/010951 external-priority patent/WO1998053817A1/en
Publication of JP2001517245A publication Critical patent/JP2001517245A/ja
Publication of JP2001517245A5 publication Critical patent/JP2001517245A5/ja
Withdrawn legal-status Critical Current

Links

JP50093899A 1997-05-29 1998-05-29 細胞接着阻害薬としてのビアリールアルカン酸類 Withdrawn JP2001517245A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US4785697P 1997-05-29 1997-05-29
GB9714316.8 1997-07-07
GBGB9714316.8A GB9714316D0 (en) 1997-07-07 1997-07-07 Biarylalkanoic acids as cell adhesion inhibitors
US6683197P 1997-11-25 1997-11-25
GB9800680.2 1998-01-14
GB60/066,831 1998-01-14
GB60/047,856 1998-01-14
GBGB9800680.2A GB9800680D0 (en) 1998-01-14 1998-01-14 Biarylalkanoic acids as cell adhesion inhibitors
PCT/US1998/010951 WO1998053817A1 (en) 1997-05-29 1998-05-29 Biarylalkanoic acids as cell adhesion inhibitors

Publications (2)

Publication Number Publication Date
JP2001517245A JP2001517245A (ja) 2001-10-02
JP2001517245A5 true JP2001517245A5 (enExample) 2005-12-02

Family

ID=27451677

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50093899A Withdrawn JP2001517245A (ja) 1997-05-29 1998-05-29 細胞接着阻害薬としてのビアリールアルカン酸類

Country Status (8)

Country Link
EP (1) EP1017382B1 (enExample)
JP (1) JP2001517245A (enExample)
AT (1) ATE318841T1 (enExample)
AU (1) AU726585B2 (enExample)
CA (1) CA2291762A1 (enExample)
DE (1) DE69833654T2 (enExample)
ES (1) ES2257808T3 (enExample)
WO (1) WO1998053817A1 (enExample)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998054207A1 (en) * 1997-05-30 1998-12-03 Celltech Therapeutics Limited Anti-inflammatory tyrosine derivatives
DE69818049T2 (de) 1997-06-23 2004-07-15 Tanabe Seiyaku Co., Ltd. Inhibitoren der alpha4-beta1 vermittelten zelladhäsion
US6362341B1 (en) 1997-07-31 2002-03-26 Athena Neurosciences, Inc. Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4
US6559127B1 (en) 1997-07-31 2003-05-06 Athena Neurosciences, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6939855B2 (en) 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method
US6492421B1 (en) 1997-07-31 2002-12-10 Athena Neurosciences, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US6423688B1 (en) 1997-07-31 2002-07-23 Athena Neurosciences, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US6489300B1 (en) 1997-07-31 2002-12-03 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
US6583139B1 (en) 1997-07-31 2003-06-24 Eugene D. Thorsett Compounds which inhibit leukocyte adhesion mediated by VLA-4
US7030114B1 (en) 1997-07-31 2006-04-18 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6291453B1 (en) 1997-07-31 2001-09-18 Athena Neurosciences, Inc. 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
ATE273273T1 (de) 1998-02-26 2004-08-15 Celltech Therapeutics Ltd Phenylalaninderivate als inhibitoren von alpha4 integrinen
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9811969D0 (en) 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
US6685617B1 (en) 1998-06-23 2004-02-03 Pharmacia & Upjohn Company Inhibitors of α4β1 mediated cell adhesion
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9821222D0 (en) 1998-09-30 1998-11-25 Celltech Therapeutics Ltd Chemical compounds
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
GB9828074D0 (en) 1998-12-18 1999-02-17 Glaxo Group Ltd Therapeutically useful compounds
CA2356969A1 (en) * 1998-12-31 2000-07-13 Aventis Pharmaceuticals Inc. 3-substituted pyrrolidines useful as inhibitors of matrix metallo-proteinases
US6486193B2 (en) 1998-12-31 2002-11-26 Aventis Pharmaceuticals Inc. 3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases
US6545003B1 (en) 1999-01-22 2003-04-08 Elan Pharmaceuticals, Inc. Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4
KR100711840B1 (ko) 1999-01-22 2007-05-02 엘란 파마슈티칼스, 인크. Vla-4 관련 질환 치료용 아실 유도체
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
EP1150997A1 (en) * 1999-01-25 2001-11-07 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by vla-4
US6407066B1 (en) 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
US6756378B2 (en) 1999-06-30 2004-06-29 Pharmacopeia Drug Discovery, Inc. VLA-4 inhibitor compounds
GB2354440A (en) * 1999-07-20 2001-03-28 Merck & Co Inc Aryl amides as cell adhesion inhibitors
ATE343383T1 (de) 1999-08-13 2006-11-15 Biogen Idec Inc Hemmer der zelladhäsion
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
US6380387B1 (en) 1999-12-06 2002-04-30 Hoffmann-La Roche Inc. 4-Pyrimidinyl-n-acyl-l phenylalanines
JP3824935B2 (ja) * 1999-12-06 2006-09-20 エフ.ホフマン−ラ ロシュ アーゲー 4−ピリミジニル−n−アシル−l−フェニルアラニン
US6388084B1 (en) 1999-12-06 2002-05-14 Hoffmann-La Roche Inc. 4-pyridinyl-n-acyl-l-phenylalanines
JP2003516392A (ja) * 1999-12-06 2003-05-13 エフ.ホフマン−ラ ロシュ アーゲー 4−ピリジニル−n−アシル−l−フェニルアラニン
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
DE19962936A1 (de) 1999-12-24 2001-06-28 Bayer Ag Neue beta-Aminosäureverbindungen als Integrinantagonisten
AU2018301A (en) 1999-12-28 2001-07-24 Pfizer Products Inc. Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
ATE375330T1 (de) 2000-04-17 2007-10-15 Ucb Pharma Sa Enamin-derivate als zell-adhäsionsmoleküle
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US6960597B2 (en) * 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
AU2001267753A1 (en) 2000-07-07 2002-01-21 Celltech R And D Limited Squaric acid derivatives containing a bicyclic heteroaromatic ring as integrin antagonists
JP2004505110A (ja) 2000-08-02 2004-02-19 セルテック アール アンド ディ リミテッド 3位置換イソキノリン−1−イル誘導体
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
YU23503A (sh) * 2000-09-29 2006-03-03 Neurogen Corporation Mali molekuli kao modulatori receptora c5a visokog afiniteta
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
SI1485127T1 (sl) 2002-02-25 2011-09-30 Elan Pharm Inc Dajanje aktivne snovi za zdravljenje vnetja
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
CN1703395A (zh) 2002-08-09 2005-11-30 特兰斯泰克制药公司 芳基和杂芳基化合物以及调节凝血的方法
WO2004041279A1 (en) 2002-10-30 2004-05-21 Merck & Co., Inc. Gamma-aminoamide modulators of chemokine receptor activity
AU2004207536B2 (en) 2003-01-24 2010-05-20 Elan Pharmaceuticals Inc. Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
WO2005014532A1 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
JP2007501844A (ja) 2003-08-08 2007-02-01 トランス テック ファーマ,インコーポレイテッド アリール及びヘテロアリール化合物、組成物並びに使用方法
GEP20094680B (en) 2004-04-13 2009-05-10 Incyte Corp Piperazinylpiperidine derivatives as chemokine receptor antagonists
FR2869904B1 (fr) * 2004-05-07 2006-07-28 Fournier S A Sa Lab Modulateurs des recepteurs lxr
CN101035563B (zh) 2004-07-08 2012-03-28 艾伦药物公司 包括聚合物部分的多价vla-4拮抗剂
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
DE602006020754D1 (de) 2005-09-29 2011-04-28 Elan Pharm Inc Carbamatverbindungen, die die durch vla-4 vermittelte leukozytenadhäsion inhibieren
AU2006297220B8 (en) 2005-09-29 2013-01-31 Elan Pharmaceuticals, Inc. Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by VLA-4
MEP1008A (xx) 2005-12-21 2010-02-10 Incyte Corp 3-aminociklopentankarboksamidi kao modulatori receptora hemokina
TWI389904B (zh) 2006-02-27 2013-03-21 Elan Pharm Inc 抑制由vla-4所調節的白血球黏附之嘧啶磺醯胺化合物
TW200811164A (en) * 2006-05-12 2008-03-01 Jerini Ag New heterocyclic compounds for the inhibition of integrins and use thereof
US20100150915A1 (en) 2007-02-20 2010-06-17 Stewart Edward J Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
KR20110008086A (ko) 2008-04-11 2011-01-25 메리맥 파마슈티컬즈, 인크. 인간 혈청 알부민 링커 및 그 콘쥬게이트
PT2370442E (pt) 2008-11-26 2013-06-27 Pfizer 3-aminociclopentanocarboxamidas como moduladores de receptor de quimiocina
CN102307875A (zh) 2009-02-09 2012-01-04 苏伯俭股份有限公司 吡咯并嘧啶基axl激酶抑制剂
MA33364B1 (fr) 2009-05-28 2012-06-01 Novartis Ag Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine
MX2011012628A (es) 2009-05-28 2011-12-14 Novartis Ag Derivados amino-propionicos sustituidos como inhibidores de neprilisina.
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
AU2014216417B2 (en) 2013-02-14 2016-05-12 Novartis Ag Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo efficacy
HRP20180958T1 (hr) 2013-02-14 2018-07-27 Novartis Ag Supstituirani derivati bisfenolbutanfosfonske kiseline kao inhibitori za nep (neutralnu endopeptidazu)
EP3116910A1 (en) 2014-03-13 2017-01-18 Prothena Biosciences Limited Combination treatment for multiple sclerosis
WO2018085578A1 (en) * 2016-11-02 2018-05-11 Saint Louis University Integrin inhibitors in combination with an agent which interacts with a chemokine receptor
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
JP7189368B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ, インコーポレイテッド アルファ4ベータ7インテグリンの阻害のための化合物
KR102630416B1 (ko) 2018-10-30 2024-02-01 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 퀴놀린 유도체
CN114222730B (zh) 2019-08-14 2024-09-10 吉利德科学公司 用于抑制α4β7整合素的化合物
AU2021289665A1 (en) 2020-06-10 2022-12-15 Aligos Therapeutics, Inc. Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections
IL309732A (en) 2021-07-09 2024-02-01 Aligos Therapeutics Inc Antiviral compounds
WO2023043816A1 (en) 2021-09-17 2023-03-23 Aligos Therapeutics, Inc. Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW223629B (enExample) * 1992-03-06 1994-05-11 Hoffmann La Roche
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
US5707985A (en) * 1995-06-07 1998-01-13 Tanabe Seiyaku Co. Ltd. Naphthyl-, quinolyl- and isoquinolyl- sulfonamide derivatives as cell adhesion modulators
US6248713B1 (en) * 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
AU728435B2 (en) * 1997-05-29 2001-01-11 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
EP1001764A4 (en) * 1997-05-29 2005-08-24 Merck & Co Inc HETEROCYCLIC AMIDE COMPOUNDS AS INHIBITORS OF CELL ADHESION

Similar Documents

Publication Publication Date Title
JP2000509912A5 (enExample)
JP2000507042A5 (enExample)
JP2000509637A5 (enExample)
JP2000509942A5 (enExample)
JP2000509635A5 (enExample)
JP2000510751A5 (enExample)
JP2000509587A5 (enExample)
JP2000507369A5 (enExample)
JP2000507433A5 (enExample)
JP2000508866A5 (enExample)
JP2000510793A5 (enExample)
JP2000508022A5 (enExample)
JP2000508841A5 (enExample)
JP2000508680A5 (enExample)
JP2000509804A5 (enExample)
JP2000509853A5 (enExample)
JP2000509755A5 (enExample)
JP2000510247A5 (enExample)
JP2000510969A5 (enExample)
JP2000508836A5 (enExample)
JP2000508102A5 (enExample)
JP2000509818A5 (enExample)
JP2000509520A5 (enExample)
JP2000507434A5 (enExample)
JP2000508880A5 (enExample)